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Abstract Refsum disease (RD) is biochemically characterized
by the excessive accumulation of phytanic acid in tissues and
body fluids due to deficiency of phytanoyl-CoA hydroxylase
(PAHX). In this study, we screened three RD patients and
identified a novel deletion (88 amino acids), and a missense
mutation (Arg275Trp) in the previously reported PAHX cDNA
(Jansen et al., 1997 ; Mihalik et al., 1997). Moreover,
transfection of skin fibroblasts from two RD patients with
wild-type PAHX gene restored the activity for K-oxidation of
phytanic acid. Southern analysis on a somatic cell hybrid panel
detected the PAHX gene on chromosome 10, corroborating
radiation hybrid and homozygosity mapping data (Mihalik et al.,
1997; Nadal et al., 1995).
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1. Introduction
Refsum disease (RD, Heredopathia atactica polyneuritifor-
mis) was ¢rst reported by Refsum in 1946 as a familial neuro-
logical syndrome which is characterized by retinitis pigmento-
sa, peripheral neuropathy, cerebral ataxia, nerve deafness and
excessive accumulation of phytanic acid in tissues and body
£uids [4,5]. Phytanic acid (3,7,11,15-tetramethylhexadecanoic
acid), a 20-carbon saturated branched-chain fatty acid, is
formed from phytol which is a derivative of the chlorophyll
molecule. Humans do not synthesize phytanic acid but con-
sume 50^100 mg/day in diet containing dairy products and
fat. Normal human plasma contains only trace amounts of
phytanic acid (6 0.3 ng/dl), whereas phytanic acid in plasma
of RD patients may account for as much as 5^30% of the
total fatty acids [5]. In addition to RD, an abnormality in
the catabolism of phytanic acid in peroxisomes also causes
its accumulation in other peroxisomal inherited metabolic dis-
orders including Rhizomelic Chondrodysplasia Punctata
(RCDP), Zellweger Syndrome (ZS), Infantile Refsum disease
(IRD) and Neonatal Adrenoleukodystrophy (NALD) [6^11].
Due to the presence of a methyl group at the L-carbon
position, the phytanic acid is ¢rst K-oxidized to pristanic
acid, which is then catabolized by L-oxidation in peroxisomes.
The oxidation of phytanic acid to pristanic acid involves acti-
vation of phytanic acid to phytanoyl-CoA, and K-hydroxyla-
tion of phytanoyl-CoA to K-hydroxyphytanoyl-CoA. This K-
hydroxyphytanoyl-CoA further undergoes dehydrogenation
to K-ketophytanoyl-CoA and decarboxylation to pristanic
acid [2,5,12^15]. The de¢cient oxidation of phytanic acid as
compared to normal oxidation of K-hydroxyphytanic acid in
cultured skin ¢broblasts of RD patients suggested a defect in
the conversion of phytanic acid to K-hydroxyphytanic acid
and this defect was attributed to the de¢cient activity of phy-
tanoyl-CoA hydroxylase (PAHX), an enzyme which catalyzes
the ¢rst reaction in the K-oxidation of phytanic acid
[7,8,11,16,17].
Recently, two research groups have simultaneously reported
the sequence of human PAHX cDNA by using partial amino
acid sequences of puri¢ed rat PAHX protein followed by the
search of EST (expressed sequence tags) database [1] or di-
rectly searching the EST database for a PTS2 (a peroxisomal
matrix protein targeting sequence) signal [2]. PAHX open
reading frame (1014 nucleotides) encodes a protein of 41.2
kDa (338 amino acids) and contains a PTS2 signal. PAHX
encoded protein is targeted to peroxisomes, interacted with
the PTS2 receptor in the yeast two-hybrid assay and had
phytanoyl-CoA hydroxylase activity [2]. Radiation hybrid
and homozygosity mapping have localized the PAHX gene
to chromosome 10 [2,3].
Skin ¢broblasts from seven RD patients were screened for
mutations in the RT-PCR derived PAHX cDNA [1,2]. This
mutational analysis has revealed point mutations or deletions
in PAHX cDNA from all examined RD patients, including a
deletion of single nucleotide (T164) causing a frame shift, a
large deletion of 37 amino acids, and missense mutations
(Asn269His or Arg275Trp). Demonstration of mutations in
the PAHX cDNA of RD patients indicated that the metabolic
abnormality may be due to defects in the PAHX gene, but
whether or not such mutations directly cause the dysfunction
of phytanic acid K-oxidation has yet to be determined. To
answer this question, we have identi¢ed the mutations in the
PAHX cDNA from three RD patients and transfected normal
PAHX cDNA into diseased ¢broblasts. The results demon-
strated the restoration of phytanic acid K-oxidation activity
in RD ¢broblasts. Also, the Southern analysis on a soma-
tic cell hybrid panel containing human monochromosomal
DNA revealed the presence of PAHX gene on chromosome
10.
2. Materials and methods
2.1. Cell lines and cell culture
Three patients (designated as 1, 2 and 3) with clinical manifesta-
tions of RD were studied. Their cultured skin ¢broblasts are defective
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in K-oxidation of phytanic acid [7,8]. Cells were maintained in Dul-
becco’s modi¢ed Eagle’s medium (DMEM, Mediatech), supplemented
with 10% bovine calf serum (HyClone).
2.2. Mutation analysis
A full-length PAHX cDNA, positions 37 to +1086 bp of the pub-
lished sequence [1], was ampli¢ed from total RNA (10 Wg) isolated
from human normal skin ¢broblasts and liver tissue. Two primer sets,
carrying an EcoRI linker, were designed based on the published se-
quence [1]. The sequence of forward primer was 5P-TTGAATTCG-
CAGCCATGGAGCAGCTTCG-3P and of reverse primer was 5P-
GCGAATTCTTGGTTTTGGTTTTCTGTTGAAAGAGTTATAG-
CAG-3P. RT-PCR ampli¢ed PAHX cDNA was digested with EcoRI
and subcloned in the unique EcoRI site of pBluescript SK+ vector
(designated as SK+PAHX). Complete sequence of the PAHX cDNA
was obtained.
PAHX cDNA was also cloned from ¢broblasts of patients 1, 2 and
3 as described for normal ¢broblasts. The PAHX cDNA clones from
these patients were completely sequenced.
2.3. Vector construction and transfection of ¢broblasts
SK+PAHX clone was digested with EcoRI and the resulting full-
length PAHX cDNA was cloned in the sense orientation into the
unique EcoRI site of pcDNA3 (Invitrogen), a mammalian expression
vector, and designated as pcDNA3PAHX. The resulting recombinant
construct was sequenced to con¢rm the orientation of the PAHX gene
in pcDNA3 vector.
pcDNA3 alone (negative control) and pcDNA3PAHX DNA (15
Wg/75 cm2 tissue culture £ask) was transfected separately into ¢bro-
blasts from normal human and RD patients using the LipoTAXI
transfection reagent, 150 Wl per 75 cm2 tissue culture £ask of 50%
cell con£uence, according to the manufacturer’s protocol (LipoTAXI
mammalian transfection kit, Stratagene).
2.4. Enzyme assay for oxidation of phytanic acid
Fibroblasts were processed for PAHX activity assay 72 h after
transfection. The assay for oxidation of [(2,3)-3H]phytanic acid was
performed essentially as described by Zenger-Hain et al. [18]. Brie£y,
K-cyclodextrin-solubilized [(2,3)-3H]phytanic acid (3 WM) was added
to ¢broblasts (25^100 Wg protein) suspended in 250 Wl of Hank’s
balanced salt solution (GIBCO BRL). The reaction was stopped by
adding 0.625 ml of 1 N KOH in methanol followed by incubation at
60‡C in a shaking water bath for 1 h. The amount of radioactivity in
the upper phase of Folch partition represented the rate of K-hydrox-
ylation of [(2,3)-3H]phytanic acid.
2.5. Determination of K-hydroxyphytanoyl-CoA formation in human
skin ¢broblasts
Formation of K-hydroxyphytanoyl-CoA from [1-14C]phytanic acid
(55 mCi/mmol) solubilized with L-cyclodextrin was studied with ¢bro-
blasts (100^150 Wg protein) suspended in 50 mM Tris pH 7.4, 5 mM
MgCl2, 0.2 mM coenzyme A, 10 mM ATP, 0.2 mM DTT, 1 mM 2-
oxoglutarate, 1 mM Fe2 and 1 mM ascorbate. Reaction mixture was
adjusted to pH 7.4. The total volume of the assay was 250 Wl con-
taining 20 WM [1-14C]phytanic acid (5 nmol). Reactions were incu-
bated for 60 min at 37‡C. After incubation, reaction mixtures were
immediately frozen at 370‡C. Samples were thawed at room temper-
ature, sonicated and applied directly on the concentrating zone of
reverse phase TLC plates (octadecylsilane bonded RPTLC, 20U20
cm, Whatman Labsales Inc.). The plate was developed in MeOH:H2O
(80:20). The chromatogram was autoradiographed and spots were
quantitated by densitometric scanning using GS-670 imaging densi-
tometer (Bio-Rad). Standard samples of 1-14C-labeled phytanic acid,
K-hydroxyphytanic acid, phytanoyl-CoA and K-hydroxyphytanoyl-
CoA were used to identify the individual products present in the
reaction mixture.
2.6. Chromosomal localization of the PAHX gene
Human monochromosomal DNA (8 Wg/somatic cell hybrid from
Mapping Panel #2, version 3, Coriell Cell Repositories) was digested
with EcoRI, electrophoresed in 0.8% agarose gel, and transferred to a
Hybond N membrane (Amersham). PAHX cDNA probe was la-
beled with 32P-dCTP using Ready-To-Go DNA labeling beads (Phar-
macia Biotech) and hybridized to immobilized DNA using Expres-
sHyb hybridization solution according to the manufacturer’s
protocol (Clontech).
3. Results
3.1. Mutational analysis of PAHX gene from RD ¢broblasts
PAHX cDNA (1026 bp) was isolated from normal human
skin ¢broblasts and liver using RT-PCR. Both ¢broblasts and
liver cDNA clones were found 100 percent identical to the
reported sequence [1,2]. This cDNA contained an open read-
ing frame of 1014 bp encoding a 338 amino acid protein.
Subsequently, PAHX cDNA was cloned from cultured skin
¢broblasts of three patients (patient 1, 2 and 3) as described
for normal ¢broblasts. The complete sequence of PAHX
cDNA clones from all three patients was obtained.
The PAHX cDNA analysis from patient 1 showed a large
deletion of 88 amino acids (amino acid numbers 138 to 225).
Deletion breakpoint in the cDNA sequence is indicated in Fig.
1A as v. PAHX cDNA from patient 2 had a single base
substitution of T for C (indicated as * in Fig. 1B) at nucleo-
tide position 823, which lead to replacement of arginine for
tryptophan (Arg275Trp). The PAHX cDNA from patient 3
carried a large deletion of 88 amino acids identical to patient 1
(v in Fig. 1C) and a missense mutation, C823T (Arg275Trp, *
in Fig. 1D) identical to patient 2. Mutational analysis on
PAHX gene from all three patients suggested that the de¢cient
activity of PAHX in RD may be due to missense mutations
and/or a large deletion in this gene.
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Fig. 1. Electropherograms depicting the sequence surrounding the
mutations in the PAHX cDNA from three RD patients as com-
pared with normal PAHX. A and C: Nucleotide sequence surround-
ing a 88 amino acid deletion (O) in PAHX cDNA from patients 1
and 3. B and D: A point mutation (*), C823T (Arg275Trp) in
PAHX cDNA from patients 2 and 3.
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3.2. Correction of phytanic acid metabolism in RD ¢broblasts
In an attempt to restore the PAHX activity in RD ¢bro-
blasts carrying mutations in the PAHX gene, RD ¢broblasts
from patients 1 and 2 were transiently transfected with the
wild-type PAHX cDNA. The results are the average of two
experiments in triplicate (Fig. 2). The K-oxidation of phytanic
acid in cultured skin ¢broblasts is reduced to 25% in patient 1
and 33% in patient 2 as compared with normal ¢broblasts
(Fig. 2). An increase of 136% and 88% PAHX activity was
observed in patients 1 and 2 (Fig. 2, patient 1+PAHX, patient
2+PAHX), respectively, as compared with RD ¢broblasts
transfected with plasmid only in transient transfection assays
(Fig. 2, patient 1+PC, patient 2+PC). This increase accounts
for 59% (patient 1) and 62% (patient 2) of normal PAHX
enzyme activity.
K-Hydroxyphytanoyl-CoA is synthesized from phytanoyl-
CoA, the ¢rst reaction in the catabolism of phytanic acid to
pristanic acid. To further con¢rm that the transgene PAHX is
functional in RD ¢broblasts, K-hydroxyphytanoyl-CoA was
determined in human cultured skin ¢broblasts by reverse
phase TLC. The results demonstrated an increase of 95% in
the level of K-hydroxyphytanoyl-CoA in transfected RD ¢bro-
blasts (Fig. 3, patient 2+PAHX) as compared to RD ¢bro-
blasts transfected with only plasmid (Fig. 3, patient 2+PC).
This increase in the metabolite is comparable to 88% increase
in PAHX enzyme activity observed in transfected RD ¢bro-
blasts (Fig. 2, patient 2+PAHX) over negative control (Fig. 2,
patient 2+PC).
These transfection studies demonstrate that transfection of
RD ¢broblasts with the PAHX cDNA restores the K-oxida-
tion of phytanic acid in RD patients and that it is responsible
for the de¢cient oxidation of phytanic acid in RD patients.
3.3. Chromosomal localization of the PAHX gene
Full-length PAHX cDNA probe (32P-labeled) was hybrid-
ized to EcoRI-digested DNA from a human/rodent somatic
cell hybrid panel. Four signals (12 kb, 7 kb, 3 kb and 2.5 kb)
were detected in chromosome 10 (Fig. 4, lane 10) and human
DNA (Fig. 4, lane 25). Two signals (12 kb and 10 kb) detected
in mouse DNA (Fig. 4, lane 26) were also visible in DNA
samples representing human chromosome numbers 1, 16, 17,
20 and 21 (Fig. 4, lanes 1, 16, 17, 20 and 21) where DNA was
from human/mouse somatic cell hybrids. These results clearly
indicate the presence of PAHX gene on chromosome 10.
4. Discussion
The identi¢cation of a number of inherited metabolic dis-
orders associated with peroxisomal dysfunction has provided
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Fig. 3. Levels of K-hydroxyphytanoyl-COA in RD and PAHX-
transfected RD cultured human skin ¢broblasts relative to normal
¢broblasts as determined by reverse phase TLC. PC: RD ¢broblasts
transfected with plasmid only (negative control). PAHX: RD ¢bro-
blasts transfected with normal PAHX gene.
Fig. 2. Restoration of peroxisomal K-oxidation of phytanic acid in
RD ¢broblasts transfected with normal PAHX gene as determined
by the release of tritium following oxidation of [(2,3)-3H]phytanic
acid. PC: RD ¢broblasts transfected with plasmid only (negative
control). PAHX: RD ¢broblasts transfected with normal PAHX
gene. Data is presented as an average of measured speci¢c activity
of PAHX as compared to control from two independent transient
transfection assays.
Fig. 4. Chromosomal localization of the PAHX gene. EcoRI-di-
gested human monochromosomal DNA was hybridized with 32P-
dCTP-labeled PAHX cDNA. Lanes 1 to 27 represent DNA (8 Wg/
lane) for human chromosomes number 1 to 22, X, Y, human,
mouse and Chinese hamster, respectively. Molecular sizes (kb) for
hybridization signals discussed in the text are indicated on the left
and with arrows on lanes.
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a stimulus to studies for elucidation of molecular events asso-
ciated with the biogenesis, disease process and biochemistry of
peroxisomes [9]. Peroxisomal K-oxidation of phytanic acid
attracted attention of several research groups because the de-
¢cient activity of PAHX enzyme causes an accumulation of
phytanic acid, presumably in cytotoxic amounts, in RD and
other peroxisomal disorders including RCDP, ZS, IRD and
NALD [1,2,6,8,10,11]. In an e¡ort to understand the metabol-
ic role of already sequenced PAHX gene [1,2], mutational
analysis was performed on three RD patients followed by
transient transfection assays in RD ¢broblasts.
Sequence analysis of PAHX cDNA from all three investi-
gated patients revealed mutations involving a novel deletion
of 88 amino acids and a missense mutation (Arg275Trp). De-
letion identi¢ed in PAHX gene of patients 1 and 3 is distinct
in sequence from an already reported deletion of 37 amino
acids in four RD patients [1,2]. However, a missense mutation
(Arg275Trp) identi¢ed in patients 2 and 3 is identical to one
reported by Mihalik et al. [2] in a RD patient. A search for
exon-exon junctions using a computer software, BCM Gene
Finder (Baylor College of Medicine, Houston, Texas) indi-
cated the presence of exon-exon junctions surrounding the
88 amino acid deleted region. Thus, this deletion might have
been caused by an exon-skipping. When an altered cDNA,
carrying a point mutation (Arg275Trp), was expressed in E.
coli, the puri¢ed protein was enzymatically inactive suggesting
that Arg275Trp is responsible for the lack of normal activity
of PAHX enzyme [2]. We observed the same mutation
(Arg275Trp) in one patient.
In transient transfection assays, an increase of PAHX ac-
tivity by 136% (patient 1) and 88% (patient 2) in PAHX-trans-
fected ¢broblasts as compared to control RD ¢broblasts
(measured as release of 3H from [(2,3)-3H]phytanic acid [18])
suggests that the PAHX restored the PAHX activity in RD
peroxisomes. This ¢nding was further con¢rmed by the ob-
servation of a comparable increase (95%) in formation of K-
hydroxyphytanoyl-CoA in PAHX-transfected RD ¢broblasts
(patient 2) relative to RD ¢broblasts transfected with plasmid
only. This observation clearly demonstrates that abnormality
in phytanic acid metabolism in RD is due to defect in the K-
hydroxylation of phytanic acid to K-hydroxyphytanoyl-CoA.
PAHX gene has been placed on human chromosome 10
based on radiation hybrid data and homozygosity mapping
[2,3]. This ¢nding was corroborated by using a human/rodent
somatic cell hybrid panel representing DNA for individual
human chromosomes. In addition, present results suggested
genomic heterogeneity between human and mouse PAHX
gene.
In conclusion, the studies reported here have identi¢ed a
novel deletion in PAHX gene, not reported previously, in
RD. Moreover, these studies have provided an evidence of
involvement of PAHX in RD.
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